Katy Beckermann, MD, PhD, discusses the latest findings from KEYMAKER-U03 Substudy 03B on pembrolizumab and targeted therapy combinations for previously treated advanced clear cell renal cell carcinoma. The phase 1/2 study evaluated the efficacy and safety of three treatment regimens: pembrolizumab + belzutifan, lenvatinib + belzutifan, and the reference arm of pembrolizumab + lenvatinib. Dr. Beckermann summarizes the key outcomes, including response rates, progression-free survival, and overall survival, as well as the safety profiles of these combinations.
KEYMAKER-U03 Substudy 03B: Evaluating Pembrolizumab and Targeted Therapy Combinations in aRCC
By Katy Beckermann, MD, PhD - Last Updated: February 21, 2025Related Posts
Drs. Beckermann and Braun discuss the latter's Nature publication on a personalized neoantigen vaccine for RCC.
Patients with mRCC on Medicare have better survival rates compared with patients on Medicaid or with no insurance.
A recent proof-of-concept study has further evaluated the efficacy of PSMA-guided MDT for oligometastatic RCC.
The panel concludes with future directions in RCC, including HIF inhibitors and biomarker-guided adjuvant strategies.
The panel considers how managing real-world patients on novel therapies like belzutifan presents a multitude of challenges.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.